Tiragolumab - Genentech
Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284Latest Information Update: 16 Aug 2024
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Liver cancer; Non-small cell lung cancer; Oesophageal cancer
- Phase II Cervical cancer; Gastric cancer; Malignant melanoma; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Phase I/II B-cell lymphoma
- No development reported Multiple myeloma
Most Recent Events
- 16 Aug 2024 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Adjuvant therapy, Neoadjuvant therapy) in USA (IV)
- 16 Aug 2024 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease, Adjuvant therapy, Neoadjuvant therapy) in Switzerland (IV)
- 16 Aug 2024 Discontinued - Phase-II for Non-small cell lung cancer (Combination therapy, Late-stage disease, Adjuvant therapy, Neoadjuvant therapy) in Germany (IV)